According to the current international guidelines, including those from the European Association of Urology (EAU) and the American Urological Association (AUA), PSMA-PET/CT is recommended for staging in patients with unfavorable intermediate-, high-, and very high-risk prostate cancer and for the detection of biochemical recurrence after radical treatment when conventional imaging is inconclusive or negative [7,8]. Here, FOLH1 is linked to prostate cancer.